The impact of kidney function on outcomes following high risk myocardial infarction: Findings from 27 610 patients

European Journal of Heart Failure

Volumn 16, Issue 3, 2014, Pages 289-299

  Moukarbel, George V ^a   Yu, Zi Fan ^b   Dickstein, Kenneth ^c   Hou, Yingxin ^b   Wittes, Janet T ^b   McMurray, John J V ^d   Pitt, Bertram ^e   Zannad, Faiez ^f   Pfeffer, Marc A ^g   Solomon, Scott D ^g  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b University of Iowa   (United States)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular outcomes; Glomerular filtration rate; Kidney function; Myocardial infarction

Indexed keywords

CREATININE;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COMORBIDITY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; INCIDENCE; KIDNEY FUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODIFICATION OF DIET IN RENAL DISEASE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; YOUNG ADULT;

CARDIOVASCULAR OUTCOMES; GLOMERULAR FILTRATION RATE; KIDNEY FUNCTION; MYOCARDIAL INFARCTION;

AGED; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE;

EID: 84896934018     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.11     Document Type: Article

References (30)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047.
2. Snyder JJ, Foley RN, Collins AJ. Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2009;53:218-228.
3. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in populationbased studies: systematic review. BMC Public Health 2008;8:117.
4. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42:1050-1065.
5. Astor BC, Hallan SI, Miller ER III, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008;167:1226-1234.
6. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47-55.
7. Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 2006;27:1245-1250.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39 Suppl 1:S1-S266.
9. Newsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW, Allison JJ. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med 2008;168:609-616.
10. Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med 2008;168:987-995.
11. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295.
12. Dickstein K, Bebchuk J, Wittes J. The high-risk myocardial infarction database initiative. Prog Cardiovasc Dis 2012;54:362-366.
13. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van De Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
14. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
15. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760.
16. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390.
17. Dargie HJ. Design and methodology of the CAPRICORN trial-a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2000;2:325-332.
18. Dickstein K, Kjekshus J. Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 2001;87:766-771.
19. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-750.
20. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
22. Levey AS, Greene T, Kusek JW, Beck GL, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000;11:155A.
23. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002;137:563-570.
24. Schiele F, Legalery P, Didier K, Meneveau N, Seronde MF, Caulfield F, Ducloux D, Bechetoille P, Magnin D, Faivre R, Bassand JP. Impact of renal dysfunction on 1-year mortality after acute myocardial infarction. Am Heart J 2006;151:661-667.
25. Inrig JK, Gillespie BS, Patel UD, Briley LP, She L, Easton JD, Topol E, Szczech LA. Risk for cardiovascular outcomes among subjects with atheroscleroti cardiovascular disease and greater-than-normal estimated glomerular filtration rate. Clin J Am Soc Nephrol 2007;2:1215-1222.
26. Cardarelli F, Bellasi A, Ou FS, Shaw LJ, Veledar E, Roe MT, Morris DC, Peterson ED, Klein LW, Raggi P. Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). Am J Cardiol 2009;103:766-771.
27. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, Anderson JL, Yusuf S. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002;39:30-36.
28. Halkin A, Stone GW, Dixon SR, Grines CL, Tcheng JE, Cox DA, Garcia E, Brodie B, Stuckey TD, Mehran R, Lansky AJ. Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. Am J Cardiol 2005;96:325-331.
29. Marenzi G, Moltrasio M, Assanelli E, Lauri G, Marana I, Grazi M, Rubino M, De Metrio M, Veglia F, Bartorelli AL. Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty. Am Heart J 2007;153:755-762.
30. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012;156:785-795.